HPV vaccination news! Many provinces are promoting market expansion soon.
Recently, various provinces and cities have successively disclosed the practical projects of people’s livelihood in 2025 and the provincial budget. According to statistics, up to now, more than ten provinces, including Beijing and Sichuan, have carried out or planned to carry out free vaccination programs for provincial-level female HPV vaccine.
According to the agency, with the successful completion of phase III clinical trials and the release of production capacity of HPV vaccine under research in China, the indications are extended to male population.ChinaThe market scale of HPV vaccine will continue to expand, and it is expected to reach 62.54 billion yuan in 2031.
Multi-provincial promotion
Since the beginning of this year, many provinces have indicated that they will launch a free vaccination program for HPV vaccine for school-age women.
Recently, Sichuan Province disclosed the "Report on the Implementation of the Budget in Sichuan Province in 2024 and the Draft Budget in 2025", which proposed to allocate 4.41 billion yuan for public health services. Improve the financial subsidy standard for basic public health services, support the implementation of "two cancers" free screening for school-age women, support the free vaccination of domestic bivalent HPV vaccine for eligible school-age girls, and increase support for AIDS prevention and treatment.
On January 26th, the General Office of the Beijing Municipal People’s Government issued the notice of "Important Livelihood Projects in Beijing in 2025", and Beijing will voluntarily vaccinate human papillomavirus vaccine for new girls in Grade One in 2025.
On January 10th, Tianjin Municipal Health and Health Commission formulated 16 measures to serve Tianjin Health and Health Kang Weimin in 2025, and explicitly launched the public welfare vaccination activities of reducing or exempting 450,000 doses of bivalent HPV vaccine for women aged 9-45.
In 2025, the work report of Yunnan provincial government put the implementation of "children’s health care and protection""Huimin Project" is listed as one of the 10 practical things to be done in 2025, and it is clearly put forward that domestic HPV vaccine should be vaccinated free of charge for eligible junior one girls in the province according to the principle of informed and voluntary.
In January this year, the government work report for 2025 released by Gansu Province made it clear that in 2025, we will continue to make overall arrangements for financial resources and do 10 practical things for the people, one of which is to subsidize HPV vaccination for 100,000 school-age girls on the premise of "knowing, volunteering and subsidizing".
In October 2024, National Health Commission held a press conference to disclose that since 2021, 11 provinces including Guangdong, Hainan, Fujian, Jiangsu, Jiangxi, Chongqing, Tibet, Zhejiang, Shandong, Hubei and Guangxi, as well as Zhengzhou,Chengdu and other cities have included HPV vaccination in the government’s practical projects for the people, and provided free HPV vaccination services for school-age girls aged 13-14 in the region through financial purchase services and fixed subsidies. Up to now, the policy of free HPV vaccination has covered about 40% of school-age girls in the country.
Speed up research and development
On January 8,It was announced that a number of new indications of tetravalent human papillomavirus vaccine (Saccharomyces cerevisiae) (trade name: Jiadaxiu, also known as tetravalent HPV vaccine) have been approved for marketing in National Medical Products Administration, which is suitable for male vaccination aged 9-26. This is the first HPV vaccine approved for male vaccination in China. Subsequently, many places announced the start of male HPV vaccination.
HPV infection is one of the most important public health problems in the world. Vaccination is the best way to prevent cervical cancer and other HPV-related cancers. Recently, in order to further respond to WHO’s Global Strategy for Accelerating the Elimination of Cervical Cancer, the International Papillomavirus Society needs to achieve the phased goal of "90-70-90" in 2030, and actively appeals to all countries to adopt a vaccination plan for both men and women as soon as possible, that is, to promote HPV vaccine equally to school-age boys and girls, so as to expand the coverage of vaccination and maximize the immune effect of the group.
Research and development of domestic nine-valent human papillomavirus vaccine is accelerated. A few days ago,It is said that the work of the phase III clinical study of the subsidiary Shanghai Zerun nine-valent HPV vaccine continues to advance. At present, the phase III clinical trial comparing the immunogenicity of this vaccine with similar vaccines is in the stage of data statistical analysis and writing clinical research reports. Based on the clinical development plan of nine-valent HPV vaccine products, the company is keeping close communication with National Medical Products Administration Drug Evaluation Center, and actively striving for the best strategy to promote the clinical research on protective efficacy.
At the end of August 2024, it was announced that the company’s nine-valent HPV vaccine marketing license application was accepted. After the application for registration of the nine-valent HPV vaccine is accepted, it still needs to go through comprehensive evaluation, on-site verification and other procedures, which will not have a significant impact on the company’s financial situation and operating performance in the short term. After being approved for listing, it will be conducive to the promotion and use of the company’s HPV vaccine, enrich the company’s product line, further enhance the company’s core competitiveness and lay a solid foundation for the company’s sustained and steady development.
Many domestic vaccine companies are also competing for the HPV vaccine market for male indications. In November 2024, it was revealed that the nine-valent HPV vaccine for male population was approved for clinical trials. In addition, on February 12, 2025,Ruike biologyIt was disclosed that the application for clinical trial of the new adjuvant recombinant nine-valent HPV vaccine developed by the company for male population was accepted in National Medical Products Administration.
It is estimated that its nine-valent HPV vaccine (female indication) will be submitted in China and Indonesia respectively in 2025.License application (BLA), nine-valent HPV vaccine (male indication) is expected to be submitted to BLA in 2027.
open-sourceIt is predicted that with the successful completion of the third phase clinical trial of HPV vaccine and the release of its production capacity, its indications will be extended to the male population, and the vaccination awareness of the target population will continue to increase, and the market scale of HPV vaccine in China will continue to expand, which is expected to reach 62.54 billion yuan in 2031.